Business
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-
About this update from Cellectar Biosciences, Inc.
[{"type":"image","alt":"Cellectar Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cellectar Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qCQXkIySESVHpCuJXj8EOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0","width":296,"height":300}},"lazy":false},{"type":"text","content":"On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia","length":204,"tagName":"p"},{"type":"text","content":"Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026","length":124,"tagName":"p"},{"type":"text","content":"Company to Hold Webcast and Conference Call at 8:30 AM ET Today","length":63,"tagName":"p"},{"type":"text","content":"FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2025, and provided a corporate update.","length":330,"tagName":"p"},{"type":"text","content":"“2025 was a productive year for Cellectar, marked by disciplined execution across our pipeline and meaningful clinical, regulatory, and operational achievements,” said James Caruso, president and CEO of Cellectar. “We advanced iopofosine I-131 toward its planned mid-2026 Conditional Marketing Authorization (CMA) submission in Europe, supported by a strong clinical dataset and productive dialogue with both the European and U.S. regulatory agencies. In parallel, we continued to shape the future of our radiotherapeutic platform with the initiation of our Phase 1b CLR 125 study in triple negative breast cancer and strengthened our supply chain and intellectual property estate.”","length":682,"tagName":"p"},{"type":"text","content":"“As we look ahead to 2026, our momentum is building. We expect important clinical readouts, continued regulatory progress, and expansion of ou...